MedPage Today

FDA Expands Durvalumab Label to Operable Lung Cancer

The FDA expanded the labeling of the immunotherapy durvalumab (Imfinzi) on Thursday to include the perioperative treatment of resectable non-small cell lung cancer (NSCLC). Approved in combination ...
MedCity News

Roche Drug Scores Label Expansion for Earlier Use in Lung Cancer

A Roche cancer drug that treats lung cancer with a certain genetic signature now has an additional FDA approval that expands the applications of the blockbuster product. The drug, Alecensa, is already ...
ascopubs.org

A phase II, open-label, combination therapy of durvalumab and ceralasertib in relapsed and refractory small cell lung cancer (SUKSES-N4).

Tumor-derived serum proteotypes to predict response to immune therapy in patients with limited disease small-cell lung cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.
Hosted on MSN

Insmed eyes Arikayce label expansion on Phase IIIb lung disease success

Insmed is looking to expand the role of its inhaled Mycobacterium avium complex (MAC) lung disease therapy, Arikayce (amikacin), following the drug’s success in a Phase IIIb trial. In the ENCORE study ...
ascopubs.org

A phase II, open-label, efficacy and safety of olaparib with bevacizumab (SUKSES-B2) in biomarker matched relapsed or refractory small cell lung cancer.

PD-(L)1 inhibitors plus anlotinib: A superior option for second-line treatment of extensive-stage small cell lung cancer. First-line immunotherapy plus chemotherapy for ES-SCLC: Comparison between ...